- The US government will allocate about 85% less Johnson and Johnson (NYSE: JNJ) COVID-19 vaccines will arrive in the states next week, data from the Centers for Disease Control and Prevention (CDC) showed.
- About 785,500 doses of J&J will be distributed, up from 4.95 million doses this week, according to Reuters.
- The New York Times reported last week that workers at the Emergent BioSolutions facility in Baltimore, which produces both AstraZeneca Plc (NASDAQ: AZN) and J&J doses mixed ingredients for two vaccines, which ruined 15 million doses of J&J.
- However, the Baltimore facility has yet to receive approval from the FDA. A federal health spokesman told Reuters last week that no dose of the plant’s vaccine has been used in vaccination campaigns so far.
- California is the top recipient of the J&J vaccine, followed by Texas and Florida, according to the CDC.
- Vaccine distribution in California has dropped by about 88% and the state is due to receive 67,600 doses next week.
- A California health official said the number would be further reduced in the week of April 18 when the state is allocated just 22,400 doses of J&J vaccine.
- J&J confirmed that it expects to deliver 100 million doses to the US government by the end of May.
- Price action: JNJ shares fell 0.26% to $ 163.19 in market trading during the last test on Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.